Correlation Between Skandinaviska Enskilda and NextCell Pharma
Can any of the company-specific risk be diversified away by investing in both Skandinaviska Enskilda and NextCell Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Skandinaviska Enskilda and NextCell Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Skandinaviska Enskilda Banken and NextCell Pharma AB, you can compare the effects of market volatilities on Skandinaviska Enskilda and NextCell Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Skandinaviska Enskilda with a short position of NextCell Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Skandinaviska Enskilda and NextCell Pharma.
Diversification Opportunities for Skandinaviska Enskilda and NextCell Pharma
-0.68 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Skandinaviska and NextCell is -0.68. Overlapping area represents the amount of risk that can be diversified away by holding Skandinaviska Enskilda Banken and NextCell Pharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NextCell Pharma AB and Skandinaviska Enskilda is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Skandinaviska Enskilda Banken are associated (or correlated) with NextCell Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NextCell Pharma AB has no effect on the direction of Skandinaviska Enskilda i.e., Skandinaviska Enskilda and NextCell Pharma go up and down completely randomly.
Pair Corralation between Skandinaviska Enskilda and NextCell Pharma
Assuming the 90 days trading horizon Skandinaviska Enskilda is expected to generate 2.17 times less return on investment than NextCell Pharma. But when comparing it to its historical volatility, Skandinaviska Enskilda Banken is 1.55 times less risky than NextCell Pharma. It trades about 0.03 of its potential returns per unit of risk. NextCell Pharma AB is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest 173.00 in NextCell Pharma AB on September 1, 2024 and sell it today you would earn a total of 2.00 from holding NextCell Pharma AB or generate 1.16% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 95.65% |
| Values | Daily Returns |
Skandinaviska Enskilda Banken vs. NextCell Pharma AB
Performance |
| Timeline |
| Skandinaviska Enskilda |
| NextCell Pharma AB |
Skandinaviska Enskilda and NextCell Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Skandinaviska Enskilda and NextCell Pharma
The main advantage of trading using opposite Skandinaviska Enskilda and NextCell Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Skandinaviska Enskilda position performs unexpectedly, NextCell Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NextCell Pharma will offset losses from the drop in NextCell Pharma's long position.| Skandinaviska Enskilda vs. Svenska Handelsbanken AB | Skandinaviska Enskilda vs. Telia Company AB | Skandinaviska Enskilda vs. Tele2 AB | Skandinaviska Enskilda vs. H M Hennes |
| NextCell Pharma vs. Diamyd Medical AB | NextCell Pharma vs. Mendus AB | NextCell Pharma vs. Vicore Pharma Holding | NextCell Pharma vs. Immunovia publ AB |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Complementary Tools
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |